Added included ADPKD rapalog trial CRAD001ADE12 and its body-weight endpoint

Added included human trial from the 2024 rapamycin/mTOR systematic review

I chased one study that was *not* in the already-extracted 8-study PMC table: the ADPKD everolimus trial subanalysis published in Journal of Cachexia, Sarcopenia and Muscle (2023).

Trial identity

* ''CRAD001ADE12'' — a 2-year randomized controlled trial in adults with autosomal-dominant polycystic kidney disease (ADPKD)
* Drug: ''everolimus'' (mTOR inhibitor / rapalog), not rapamycin itself

Extracted primary endpoint / main outcome focus

The publication’s abstract explicitly centers on ''body weight course'' and reports ''sex-specific body weight loss'' during everolimus therapy, especially in women.

Key abstract facts (verbatim-level summary)

- Trial population: 433 adult ADPKD patients (everolimus n=215; placebo n=218)
- The authors state that within the 2-year CRAD001ADE12 trial, women on everolimus lost more weight than placebo (P=0.0029)
- They also report lower caloric intake and altered thermogenesis/fat oxidation on everolimus

Why this matters for the mission

This is a concrete example of how the 2024 review’s 19 included studies are broader than the earlier 8-study completed-table snapshot: it adds an ADPKD / metabolic outcome study under the same mTOR-inhibition umbrella.

Citation trail

- PubMed record: Mammalian target of rapamycin inhibition impacts energy homeostasis and induces sex-specific body weight loss in humans
- MDC repository page exposes the abstract and trial name ''CRAD001ADE12''

Reproducible extraction note

CRAD001ADE12
primary outcome focus: body weight course / sex-specific body weight loss
population: ADPKD adults
agent: everolimus